Today: 30 June 2026
CrowdStrike stock falls while the S&P rises — what CRWD investors are watching next
21 January 2026
1 min read

CrowdStrike stock falls while the S&P rises — what CRWD investors are watching next

New York, Jan 21, 2026, 14:14 EST — Regular session

  • CrowdStrike shares slipped roughly 0.2% in afternoon trading following a volatile session
  • The company cites a commissioned Forrester study and is ramping up efforts with a new “data sovereignty” cloud initiative
  • Cybersecurity names are split, as Palo Alto slips while Zscaler climbs

Shares of CrowdStrike Holdings, Inc. slipped roughly 0.2% to $441.73 in afternoon trading Wednesday, moving between $439.83 and $456.01 during the session.

Recent headlines highlight two key themes resonating with customers and regulators alike: demonstrating that security investments deliver returns, and pinpointing the location of sensitive data. For CrowdStrike, these issues directly impact how it markets the Falcon platform and its pace of expansion beyond the U.S.

The stock was already struggling before the recent reports. CrowdStrike dropped 2.46% on Tuesday, marking its fourth day of losses in a row, and it now trades roughly 22% below its 52-week peak, MarketWatch data show.

CrowdStrike revealed Wednesday that a Total Economic Impact study by Forrester Consulting showed a composite company switching from legacy endpoint security to CrowdStrike gained a 273% ROI over three years, recouping costs in less than six months. “Modern endpoint security isn’t just more effective, it’s more economically rational,” said Chief Technology Officer Elia Zaitsev. CrowdStrike

Just a day before, CrowdStrike revealed plans to launch new regional cloud deployments within Saudi Arabia, India, and the United Arab Emirates as part of its Global Data Sovereignty initiative. The goal: ensure customer data remains local while maintaining access to CrowdStrike’s global telemetry and threat intelligence.

Chief Executive George Kurtz argued that data sovereignty mandates “cannot come at the cost of AI-powered security,” presenting the expansion as a means to maintain a unified defense framework amid increasingly strict local regulations. nasdaq.com

Cybersecurity stocks showed a mixed picture. Palo Alto Networks dropped roughly 2.1%, Fortinet edged down about 0.6%, but Zscaler climbed near 1.4%. SentinelOne dipped just a bit. The SPDR S&P 500 ETF gained around 0.5%.

However, the cloud expansion remains in the planning stages, not yet complete. CrowdStrike highlighted risks and uncertainties tied to the upcoming deployments, warning that actual results might vary significantly.

The upcoming earnings report is the next major milestone, where management will need to clarify timing and demand amid the new outlook. Nasdaq’s earnings calendar currently projects CrowdStrike’s report date to be around March 3.

Traders are watching to see if the stock holds steady after its recent drop — and whether “data sovereignty” shifts from buzzword to a tangible factor in the upcoming figures.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals
Previous Story

UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals

Accenture stock price rises as Palantir-backed “sovereign AI” data-center deal grabs focus
Next Story

Accenture stock price rises as Palantir-backed “sovereign AI” data-center deal grabs focus

Go toTop